 HSP90 Heat-Shock Proteins
"HSP90 Heat-Shock Proteins" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A class of MOLECULAR CHAPERONES whose members act in the mechanism of SIGNAL TRANSDUCTION by STEROID RECEPTORS.
| Descriptor ID |
D018841
|
| MeSH Number(s) |
D12.776.580.216.380
|
| Concept/Terms |
HSP90 Heat-Shock Proteins- HSP90 Heat-Shock Proteins
- HSP90 Heat Shock Proteins
- Heat-Shock Proteins, HSP90
- Heat-Shock Proteins 90
- Heat Shock Proteins 90
|
Below are MeSH descriptors whose meaning is more general than "HSP90 Heat-Shock Proteins".
Below are MeSH descriptors whose meaning is more specific than "HSP90 Heat-Shock Proteins".
This graph shows the total number of publications written about "HSP90 Heat-Shock Proteins" by people in this website by year, and whether "HSP90 Heat-Shock Proteins" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 | | 2000 | 1 | 1 | 2 | | 2001 | 0 | 1 | 1 | | 2003 | 1 | 1 | 2 | | 2004 | 1 | 1 | 2 | | 2007 | 0 | 1 | 1 | | 2008 | 2 | 0 | 2 | | 2009 | 1 | 0 | 1 | | 2011 | 1 | 2 | 3 | | 2012 | 1 | 0 | 1 | | 2013 | 0 | 1 | 1 | | 2014 | 3 | 1 | 4 | | 2015 | 3 | 1 | 4 | | 2016 | 2 | 1 | 3 | | 2017 | 0 | 1 | 1 | | 2018 | 6 | 0 | 6 | | 2019 | 1 | 1 | 2 | | 2020 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "HSP90 Heat-Shock Proteins" by people in Profiles.
-
Gorska-Ponikowska M, Kuban-Jankowska A, Marino Gammazza A, Daca A, Wierzbicka JM, Zmijewski MA, Luu HH, Wozniak M, Cappello F. The Major Heat Shock Proteins, Hsp70 and Hsp90, in 2-Methoxyestradiol-Mediated Osteosarcoma Cell Death Model. Int J Mol Sci. 2020 Jan 17; 21(2).
-
Vaddi DR, Piao L, Khan SA, Wang N, Prabhakar NR, Nanduri J. Hypoxia induced hERG trafficking defect linked to cell cycle arrest in SH-SY5Y cells. PLoS One. 2019; 14(4):e0215905.
-
Ocaña GJ, Sims EK, Watkins RA, Ragg S, Mather KJ, Oram RA, Mirmira RG, DiMeglio LA, Blum JS, Evans-Molina C. Analysis of serum Hsp90 as a potential biomarker of ß cell autoimmunity in type 1 diabetes. PLoS One. 2019; 14(1):e0208456.
-
Shah S, Luke JJ, Jacene HA, Chen T, Giobbie-Hurder A, Ibrahim N, Buchbinder EL, McDermott DF, Flaherty KT, Sullivan RJ, Lawrence DP, Ott PA, Hodi FS. Results from phase II trial of HSP90 inhibitor, STA-9090 (ganetespib), in metastatic uveal melanoma. Melanoma Res. 2018 12; 28(6):605-610.
-
Lee J, Zhang LL, Wu W, Guo H, Li Y, Sukhanova M, Venkataraman G, Huang S, Zhang H, Alikhan M, Lu P, Guo A, Galanina N, Andrade J, Wang ML, Wang YL. Activation of MYC, a bona fide client of HSP90, contributes to intrinsic ibrutinib resistance in mantle cell lymphoma. Blood Adv. 2018 08 28; 2(16):2039-2051.
-
Nakamoto H, Amaya Y, Komatsu T, Suzuki T, Dohmae N, Nakamura Y, Jantan I, Miyata Y. Stimulation of the ATPase activity of Hsp90 by zerumbone modification of its cysteine residues destabilizes its clients and causes cytotoxicity. Biochem J. 2018 08 16; 475(15):2559-2576.
-
Li M, Mulkey F, Jiang C, O'Neil BH, Schneider BP, Shen F, Friedman PN, Momozawa Y, Kubo M, Niedzwiecki D, Hochster HS, Lenz HJ, Atkins JN, Rugo HS, Halabi S, Kelly WK, McLeod HL, Innocenti F, Ratain MJ, Venook AP, Owzar K, Kroetz DL. Identification of a Genomic Region between SLC29A1 and HSP90AB1 Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance). Clin Cancer Res. 2018 10 01; 24(19):4734-4744.
-
Starr TN, Flynn JM, Mishra P, Bolon DNA, Thornton JW. Pervasive contingency and entrenchment in a billion years of Hsp90 evolution. Proc Natl Acad Sci U S A. 2018 04 24; 115(17):4453-4458.
-
Zheng X, Beyzavi A, Krakowiak J, Patel N, Khalil AS, Pincus D. Hsf1 Phosphorylation Generates Cell-to-Cell Variation in Hsp90 Levels and Promotes Phenotypic Plasticity. Cell Rep. 2018 03 20; 22(12):3099-3106.
-
Qin J, Kunda N, Qiao G, Calata JF, Pardiwala K, Prabhakar BS, Maker AV. Colon cancer cell treatment with rose bengal generates a protective immune response via immunogenic cell death. Cell Death Dis. 2017 02 02; 8(2):e2584.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|